Search
Silexion Therapeutics Corp
SLXNAdd to Watchlist
0.436USD
+0.056+14.74%
Close 09-18 16:00（ET）
519.13KMarket Cap
LossP/E TTM
After-hours 19:41 (ET)0.392USD-0.048-10.91%
After-hours 19:41 (ET)SLXN Analyst Recommendation Trends
In the current month, SLXN has received 1 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SLXN average Analyst price target in the last month is 60.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
1
1
2
2
2
2
2
2
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
Financial Forecasting
Based on analysts' estimates, SLXN EPS is projected to reach -0.910 in FY2026Q3, following reported EPS of -5.166 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-11.20
-12.90
-2.12
-0.91
-0.71
Actual
-1.40
-8.46
-5.17
--
--
Surprise
+87.48%
+34.42%
-143.69%
--
--
FAQs
How have Silexion Therapeutics CorpSLXN's recent earnings per share performed?
The market expectation was USD -5.17, while Silexion Therapeutics CorpSLXN's earnings per share (EPS) for the previous quarter was USD -8.46. EPS for the next quarter is expected at USD -0.91.
What is the analyst rating for Silexion Therapeutics Corp?
Based on the ratings of Silexion Therapeutics Corp's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.